Literature DB >> 18795074

Expression of multidrug resistance-related protein (MRP-1), lung resistance-related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms' tumor: immunohistochemical study using TMA methodology.

Eduard Fridman1, Jozef Skarda, Jonatan H Pinthus, Jonathan Ramon, Yoran Mor.   

Abstract

AIMS: MRP-1, LRP and TOPO-II are all associated with protection of the cells from the adverse effects of various chemotherapeutics. The aim of this study was to measure the expression of these proteins in Wilms' tumor (WT).
MATERIALS AND METHODS: TMA block was constructed from 14 samples of WT's and from xenografts derived from them. Sections of the TMA were used for immunostaining against MRP-1, LRP and TOPO-IIa.
RESULTS: All normal kidneys expressed MRP-1 but were either weakly or negatively stained for LRP and TOPO-IIa. In WT samples, MRP-1 was universally expressed, exclusively in the tubular component, while there was no expression of LRP and TOPO-IIa showed heterogeneous distribution. The xenografts varied in their MRP-1 and TOPO-IIa expression and exhibited weak/negative staining of LRP.
CONCLUSIONS: This study shows that although all the proteins evaluated, had different expression patterns in the tumor samples, the most prominent changes in expression were found for MRP-1. The exact clinical implications of these changes in expression and their relevance to the resistance of these tumors to chemotherapy requires further investigation. The finding of different expression profiles for the multidrug resistance proteins in the original WT's and their xenografts suggests that the results of animal cancer models may be difficult to interpret.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795074     DOI: 10.5507/bp.2008.007

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  4 in total

1.  The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line.

Authors:  Weifeng Zhao; Shuyuan Liu; Qian Dou; Changan Li; Jingpei DU; Weihua Ren
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

Review 2.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

3.  Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer.

Authors:  Shanthi Ganesh; Arun K Iyer; Jan Weiler; David V Morrissey; Mansoor M Amiji
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-30       Impact factor: 10.183

4.  sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.

Authors:  Guoliang Ma; Hengjuan Cai; Lizhen Gao; Mei Wang; Haixia Wang
Journal:  World J Surg Oncol       Date:  2015-02-25       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.